Related Experiment Video
Updated: Jan 8, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
ADAM17-dependent Autocrine and Paracrine Signaling Promotes Pancreatic Premalignant Progression
Hui-Ju Wen1, Erick T Davis1, Jacee S Moore1
1Department of Surgery, Henry Ford Health System, Detroit, Michigan.
Background & Aims:
A Disintegrin and Metalloproteinase 17 (ADAM17) is a membrane-bound sheddase that regulates the release of multiple signaling molecules, including inflammatory mediators and epidermal growth factor receptor (EGFR) ligands. Ligand-driven EGFR activation is essential for pancreatic acinar cell transdifferentiation into metaplastic ducts, which progress to neoplasia in the presence of oncogenic KrasG12D. The aim of this study is to understand how ADAM17 in the tumor and myeloid cells contribute to the initiation and progression of pancreatic tumors.
Methods:
KRASG12D-driven pancreatic tumorigenesis models with parenchymal gene ablation (Egfrf/f;KrasLSL-G12D/+;Ptf1aCre/+ and Adam17f/f;KrasLSL-G12D/+;Ptf1aCre/+) and dual recombinase mouse models with KrasG12D expression in the parenchyma and gene deletion in myeloid cells (KrasFSF-G12D/+;Ptf1aFlpO/+;LysM-Cre;Adam17f/ff) were generated to investigate the functional contributions of ADAM17 in different cell types. An intervention study using an ADAM17-blocking antibody to treat KrasLSL-G12D/+;Ptf1aCre/+ mice after tumor initiation was conducted.
Results:
Genetic deletion of Adam17 in pancreatic parenchymal cells blocked KRASG12D-induced metaplasia/neoplasia and inhibited macrophage infiltration. Ablation of Adam17 in myeloid cells did not prevent initial metaplastic duct formation but impeded neoplastic progression. Pharmacological inhibition of ADAM17 compromised multiple oncogenic signaling cascades, reverted premalignant ductal lesions to an acinar state, and resolved the fibro-inflammatory response, despite continued KRASG12D expression.
Conclusions:
KRASG12D-driven tumorigenesis requires both autocrine and paracrine signaling regulated by ADAM17. Beyond activating EGFR to drive acinar cell transdifferentiation, ADAM17 also promotes neoplastic progression by modulating additional pro-tumor signaling that shapes the fibroinflammatory microenvironment. These findings highlight a pivotal role for ADAM17 in orchestrating epithelial plasticity, cellular signaling, and stromal remodeling during pancreatic tumorigenesis.
Related Concept Videos
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Insulin Secretory Vesicles
PI3K/mTOR/AKT Signaling Pathway

